| Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. (NCT07448116) | Betta Pharmaceuticals Co., Ltd. | 2026-01-31 |
| Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI (NCT07181499) | Betta Pharmaceuticals Co., Ltd. | 2025-09-01 |
| Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. (NCT06885840) | Betta Pharmaceuticals Co., Ltd. | 2025-03-31 |
| A Phase I Study of CFT8919 in Patients With Advanced NSCLC (NCT06641609) | Betta Pharmaceuticals Co., Ltd. | 2024-12-13 |
| A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers (NCT06492525) | Betta Pharmaceuticals Co., Ltd. | 2024-07-01 |
| Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation (NCT06015568) | Betta Pharmaceuticals Co., Ltd. | 2023-09-01 |
| BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors (NCT05869240) | Betta Pharmaceuticals Co., Ltd. | 2023-05-16 |
| A Study of BPI-452080 in Subjects With Solid Tumors (NCT05843305) | Betta Pharmaceuticals Co., Ltd. | 2023-04-28 |
| A Study of BPI-460372 in Advanced Solid Tumor Patients (NCT05789602) | Betta Pharmaceuticals Co., Ltd. | 2023-04-24 |
| Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations (NCT06041776) | Betta Pharmaceuticals Co., Ltd. | 2023-03-28 |
| A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma (NCT05341557) | Betta Pharmaceuticals Co., Ltd. | 2022-08-29 |
| Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients (NCT05369312) | Betta Pharmaceuticals Co., Ltd. | 2022-06-01 |
| A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer (NCT05433480) | Betta Pharmaceuticals Co., Ltd. | 2022-05-25 |
| Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NCT05341583) | Betta Pharmaceuticals Co., Ltd. | 2022-05-24 |
| A Food-Effect Study of BPI-16350 in Healthy Subjects (NCT05316259) | Betta Pharmaceuticals Co., Ltd. | 2022-04-15 |
| A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 (NCT05341570) | Betta Pharmaceuticals Co., Ltd. | 2022-01-19 |
| Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors (NCT04930432) | Betta Pharmaceuticals Co., Ltd. | 2021-09-24 |
| A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors (NCT05315180) | Betta Pharmaceuticals Co., Ltd. | 2021-08-24 |
| Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer (NCT05007938) | Betta Pharmaceuticals Co., Ltd. | 2021-08-12 |
| A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors (NCT05329298) | Betta Pharmaceuticals Co., Ltd. | 2021-07-21 |
| A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (NCT04946890) | Betta Pharmaceuticals Co., Ltd. | 2021-07-01 |
| A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors (NCT05302843) | Betta Pharmaceuticals Co., Ltd. | 2021-03-22 |
| The Absorption, Metabolism and Excretion of [14C]D-0316 in Human (NCT04464551) | Betta Pharmaceuticals Co., Ltd. | 2020-12-05 |
| D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC (NCT04206072) | Betta Pharmaceuticals Co., Ltd. | 2019-12-24 |
| A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor (NCT03791112) | Betta Pharmaceuticals Co., Ltd. | 2019-07-18 |
| The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human (NCT03804541) | Betta Pharmaceuticals Co., Ltd. | 2018-12-28 |
| Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation (NCT03754530) | Betta Pharmaceuticals Co., Ltd. | 2018-12-01 |
| Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer (NCT03749213) | Betta Pharmaceuticals Co., Ltd. | 2018-12-01 |
| A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy (NCT04058704) | Betta Pharmaceuticals Co., Ltd. | 2018-07-20 |
| X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement (NCT03608007) | Betta Pharmaceuticals Co., Ltd. | 2018-06-15 |
| Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer (NCT03396185) | Betta Pharmaceuticals Co., Ltd. | 2018-05-09 |
| A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers. (NCT03510611) | Betta Pharmaceuticals Co., Ltd. | 2018-03-12 |
| Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis (NCT03222622) | Betta Pharmaceuticals Co., Ltd. | 2017-11-29 |
| Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer (NCT03346811) | Betta Pharmaceuticals Co., Ltd. | 2017-11-18 |
| X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib (NCT03215693) | Betta Pharmaceuticals Co., Ltd. | 2017-09-28 |